Sudeep Pharma FY26 Performance: Revenue Climbs 27.9%, PAT Up 25.7%

Revenue from operations reached ₹642.3 crore in FY26, a 27.9% year-on-year increase from ₹501.9 crore in FY25. Profit After Tax (PAT) grew by 25.7% to ₹174.3 crore in FY26, up from ₹138.7 crore in the previous year.

Reader Takeaway: Strong revenue growth driven by expansion; temporary margin dip due to strategic investments.

What just happened

Sudeep Pharma Limited announced its financial results for the fiscal year ending March 31, 2026 (FY26). The company reported a significant 27.9% year-on-year (YoY) increase in revenue from operations, reaching ₹642.3 crore. Profit After Tax (PAT) also saw a substantial jump of 25.7% YoY, amounting to ₹174.3 crore.

However, the company's EBITDA margin experienced a decline, falling to 34.6% in FY26 from 37.8% in FY25, a reduction of 3.2 percentage points. This compression in margins has been attributed by the management to upfront costs associated with building teams, warehousing, and inventory in Europe and North America.

Why this matters

The robust revenue and PAT growth indicate strong market demand and successful expansion strategies. The increase in revenue, particularly in the Pharma Food & Nutrition segment, suggests underlying volume growth. The proactive increase in raw material inventory to mitigate supply chain risks, though increasing working capital, highlights a focus on operational resilience. The ongoing investments in new projects like battery materials signal future growth potential.

The backstory

In FY25, Sudeep Pharma reported revenue of ₹501.9 crore and PAT of ₹138.7 crore. The company has been focused on expanding its geographical presence and product portfolio. The current fiscal year's performance shows a continuation of its growth trajectory, albeit with a short-term impact on profitability margins due to strategic investments.

What changes now

Investors will be closely watching the normalization of EBITDA margins as the strategic investments in Europe and North America begin to yield returns. Management's target to reduce the net working capital cycle to 150-160 days from the current 213 days in FY27 will be a key focus. The progress on the Battery Materials (SAM) project, with Phase 1 capacity expected by April 2027, presents a significant future growth avenue.

Risks to watch

The temporary margin compression due to expansion costs is a key short-term concern. The increase in working capital days also needs to be managed effectively. The success of the new battery materials venture and the integration of the NSS acquisition in Europe are critical for sustained future growth.

Peer comparison

While specific peer comparisons were not provided in the filing, the company's revenue growth of 27.9% appears robust. The company's net debt-to-equity ratio of 0.04x indicates a strong and conservative balance sheet compared to many industry peers who may carry higher leverage.

Context metrics (time-bound)

• FY26 Revenue: ₹642.3 crore (up 27.9% YoY)
• FY26 PAT: ₹174.3 crore (up 25.7% YoY)
• FY26 EBITDA Margin: 34.6% (down 3.2 pp YoY)
• Q4 FY26 Revenue: ₹182.3 crore (up 15.7% YoY)
• Net Debt (March 31, 2026): ₹33.6 crore
• Net Debt-to-Equity (March 31, 2026): 0.04x
• Working Capital Days (March 31, 2026): 213 days (up from 184)

What to track next

Investors should track the company's progress in normalizing working capital days, the impact of new investments on EBITDA margins in upcoming quarters, and the commercialization progress of the battery materials project.